KRMD Q4 2025 Earnings Call Summary

KORU Medical Systems (KRMD) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Q4 Revenue: $10.9 million, representing a 23% year-over-year growth.
Full Year Revenue: $41.1 million, up 22% from $33.6 million in 2024.
Domestic Core Growth: 18% in Q4; 11% for the full year.
International Core Growth: 71% in Q4; 80% for the full year.
Gross Margin: 62.3% for the full year, with a slight decrease in Q4 due to higher material costs.
Cash Position: $8.9 million at year-end, with positive cash flow from operations achieved in Q3 and Q4.
Adjusted EBITDA: Positive at $600,000, marking a 124% improvement year-over-year.

2. Strategic Updates and Business Highlights

Leadership Transition: CEO Linda Tharby announced her retirement effective June 30, 2026, with Adam Kalbermatten appointed as her successor.
Regulatory Milestones: Received EU MDR certification for the FREEDOM60 system and 510(k) clearance for RYSTIGGO, expanding the product line into non-IG therapies.
Patient Base Growth: Increased recurring revenue base to approximately 59,000 global chronic SCIg patients.
New Collaborations: Announced two new pharma collaborations targeting a Phase III nephrology drug and a Phase I multi-indication drug.
Market Position: Gained market share in Europe, increasing from 10% to 20% in the SCIg pump and consumables market.

3. Forward Guidance and Outlook

2026 Revenue Guidance: $47.5 million to $50 million, indicating growth of 15% to 22%.
Gross Margin Expectation: 61% to 63% for the full year.
Profitability Goals: Positive adjusted EBITDA and cash flow expected for the full year, with operational leverage anticipated as revenue grows.

4. Challenges and Points of Concern

PST Business Decline: Experienced a 30% year-over-year decrease, attributed to the timing of contract milestones.
Geopolitical Risks: Incorporated potential geopolitical risks into guidance, particularly related to events in the Middle East.
Market Penetration: Despite strong growth, the overall penetration of SCIg remains below 20% in the U.S., indicating room for improvement but also competitive pressures.

5. Notable Q&A Insights

Market Dynamics: The company is capitalizing on the shift from hospital to home care, particularly in large-volume subcutaneous drug delivery.
Future Growth Drivers: Anticipated growth from new drug approvals and the expansion of prefilled syringe conversions in international markets.
Operating Leverage: Management highlighted the discipline in controlling operating expenses, with expectations for continued operating leverage in 2026.
Oncology Market Entry: The approval of RYSTIGGO is expected to facilitate entry into the oncology market, with potential for significant growth as new drugs are added to the pipeline.

Overall, KORU Medical Systems demonstrated strong financial performance in 2025, with strategic initiatives positioning the company for continued growth, despite some challenges in specific business segments and external market conditions.

KRMD — KORU Medical Systems, Inc.